Fourth, we did not investigate how indicating or withholding osteoporosis treatments (such as bisphosphonates, activated vitamin D, or RANKL inhibitors) might influence prognosis in patients with low BMD. The gene discussed is TNFSF11; the disease is osteoporosis.